While biopharma share prices plummeted recently after President-elect Donald Trump promised to let Robert F. Kennedy Jr. “go wild” reforming government health programs, a senior US Food and Drug Administration leader attempted to reassure industry that the agency will not be undermined.
Marks Believes Trump Team Will Not Threaten US FDA’s Medicines Expertise
The US FDA’s Peter Marks told the Jefferies meeting that scientific leadership will be protected and that the agency wants to do more to help the sector accelerate innovation.
